小剂量锂剂在糖尿病肾病中作用研究进展  

Role of low-dose lithium in diabetic nephropathy

作　　者：熊秋月 邵凤民 阎磊 XIONG Qiu-yue;SHAO Feng-min;YAN Lei(Department of Nephrology,Zhengzhou University People’s Hospital,Henan Provincial People’s Hospital,Henan Provincial Key Laboratory of Nephrology and Immunology,Henan Provincial Clinical Research Center for Kidney Disease,Zhengzhou,Henan 450003,China)

机构地区：[1]郑州大学人民医院河南省人民医院肾内科河南省肾脏病免疫重点实验室河南省肾病临床医学研究中心,河南郑州450003

出　　处：《中华实用诊断与治疗杂志》2022年第6期586-588,共3页Journal of Chinese Practical Diagnosis and Therapy

基　　金：河南省重大科技专项(201300310700)。

摘　　要：糖尿病肾病是糖尿病患者的微血管并发症,发病率呈上升趋势,可导致终末期肾病,其发病机制尚不明确。糖尿病肾病患者肾组织糖原合成酶激酶3β的表达明显增高,动物实验表明锂剂可负向调控糖原合成酶激酶3β,可能是糖尿病肾病治疗的新方法。本文就小剂量锂剂在糖尿病肾病中肾脏保护作用的动物实验研究进展作一综述。Diabetic nephropathy is a microvascular complication of diabetes with an increasing incidence,leading to end-stage renal disease.The pathogenesis remains unclear.Glycogen synthase kinase-3βexpression increases significantly in the renal tissues of patients with diabetic nephropathy.The animal experiments showed that lithium could negatively regulate glycogen synthase kinase-3β,which might be a new treatment method for diabetic nephropathy.This paper reviews the animal research progress of protective effect of low-dose lithium on kidney in diabetic nephropathy.

关 键 词：糖尿病肾病 糖原合成酶激酶3Β 锂剂 

分 类 号：R587.2[医药卫生—内分泌] R692.9[医药卫生—内科学]